MedTrace Logo

Study for Safety and Tolerability of TOP1288 Administered Orally in Healthy Subjects

NCT03071081 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2018-09-20

No results posted yet for this study

Summary

This study evaluates the safety and tolerability of TOP1288 oral single ascending and multiple doses in healthy subjects.

Conditions

Interventions

DRUG

TOP1288

Oral TOP1288

DRUG

Placebo to TOP1288

Oral placebo to TOP1288

Sponsors & Collaborators

  • Topivert Pharma Ltd

    lead INDUSTRY

Principal Investigators

  • Muna Albayaty, MBChB, FFPM · Copenhagen Trial Unit, Center for Clinical Intervention Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-02-08
Primary Completion
2017-06-02
Completion
2017-06-02

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03071081 on ClinicalTrials.gov